LLY · News · 20260922N
Manufacturing Capacity Expansion
ELI LILLY & Co · 2026-09-22 · Importance 52 · Surprise 42 · In source text
Eli Lilly is building a new $6.5 billion facility in Houston to produce the active ingredient for oral obesity treatment Foundayo. The facility is targeted to begin operations by 2030 and is intended to support expanding demand for the drug. Management also plans to introduce Foundayo in additional international markets, with potential demand expansion into type 2 diabetes and from anticipated Medicare obesity-treatment coverage.
Key facts
- Eli Lilly aims to launch operations at the new Houston facility by 2030. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | probable | — | Eli Lilly aims to launch operations at the new Houston facility by 2030. |